(#4882S), TNF-α (#6945s), TNF-α neutralizing antibody (7321s), and TNFR1 (#3736S) were purchased from Cell Signaling Technology Inc.; GAPDH (#sc-47724) was from Santa Cruz Biotechnology (SC); LC3 (#NB100-2220) was from Novus Biologicals. Z-VAD-FMK (#V116) and Necrostatin-1(#N9037) were from Sigma. IKK-16(#S2882) from Selleck'.
In the Results, APG-1387 is RIP1-dependent in ovarian cancer induced apoptosis section there was an error: 'We examined the protein levels of caspase-8/RIP1 by western blot, as shown in Fig. 4a '.
Should instead read: 'We examined the protein levels of caspase-8/RIP1 by western blot. APG-1387 triggered the activation of caspase-8 and downregulated the protein level of RIP1, as shown in Fig. 4a '.
In the Results, APG-1387 induces apoptotic cell death through engagement of TNFR1 by TNF-alpha signaling pathway section there was an error: 'We have investigated the expression of NF-κB1/p50 and NF-κB2/p52 by western blot after cells were incubated with various concentrations of APG-1387'.
Should instead read: 'These results demonstrate that TNFα signaling is required for APG-1387-induced apoptotic cell death. Next, we have investigated the expression of NF-κB1/p50 and NF-κB2/p52 by western blot after cells were incubated with various concentrations of APG-1387'.
A section header contained an error: ' APG-1387-induced autophagy' Should instead read: ' APG-1387 induces autophagy in ovarian cancer ' A section header contained an error: ' APG-1387-induced apoptosisby modulating autophagy' Should instead read: 'Inhibition of autophagy sensitizes ovarian cancer cells to A PG-1387-induced apoptosis'.
In the Discussion section there was an error: ' APG-1387 is a novel Smac mimetic. In our study, we investigated the molecular mechanisms underlying the inhibitory effect on the growth of ovarian cancer cell lines treated with varying concentrations of APG-1387'.
Should instead read: 'Restoring the apoptotic cell death machinery by pharmacological inhibition of IAPs proteins represents a compelling strategy for cancer therapy. APG-1387 is a novel Smac mimetic developed by Ascentage and currently being evaluated in phase I clinical trial. In our study, we investigated the in vitro and in vivo antitumor activity of APG-1387 in ovarian cancer'.
In the Discussion section there was an error: 'Our results suggest that APG-1387 induces autophagy during apoptosis. Autophagy plays a role in protecting cell survival. We have also found that it was effective as a single agent in vivo models. Treatment with APG-1387 induced potent cytotoxic and antiproliferative activity against established and human ovarian cancer cells'.
Should instead read: 'Our results suggest that APG-1387 induces autophagy while triggering apoptosis. APG-1387-induced autophagy plays a role in protecting cell survival and inhibition of autophagy potentiates cytotoxicity of APG-1387 in ovarian cancer cells'. This has now been updated in the original article [1] . 
